Collins Gregory T, France Charles P
Department of Pharmacology, University of Texas Health Science Center at San Antonio.
Exp Clin Psychopharmacol. 2018 Oct;26(5):488-496. doi: 10.1037/pha0000209. Epub 2018 Jun 28.
Cocaine use disorder is a serious public health issue for which there is no effective pharmacotherapy. One strategy to speed development of medications for cocaine use disorder is to repurpose drugs already approved for use in humans based on their ability to interact with targets known to be important for addiction. Two such drugs, lorcaserin (Belviq; a drug with serotonin [5-HT]2C receptor agonist properties) and buspirone (Buspar; a drug with 5-HT1A receptor partial agonist and dopamine D3/D4 receptor antagonist properties) can produce modest decreases in cocaine self-administration in rhesus monkeys. The current study evaluated the effectiveness of mixtures of lorcaserin and buspirone (at fixed dose ratios of 3:1, 1:1, and 1:3 relative to each drug's ID50) to reduce responding for 0.032 mg/kg/inf cocaine under a progressive ratio schedule of reinforcement in 2 male and 2 female rhesus monkeys. Dose addition analyses were used to determine if the effects of the drug mixtures differed from those predicted for an additive interaction between lorcaserin and buspirone. Dose-dependent reductions of cocaine self-administration were observed when lorcaserin and buspirone were administered alone, as well as when they were administered as 3:1, 1:1, and 1:3 fixed ratio mixtures of lorcaserin + buspirone. The effects of the 1:1 mixture of lorcaserin + buspirone on cocaine self-administration were supraadditive, whereas the effects of 3:1 and 1:3 mixtures were additive. Together, these results indicate that a combination therapy containing a mixture of lorcaserin and buspirone might be more effective than either drug alone at treating cocaine use disorder. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
可卡因使用障碍是一个严重的公共卫生问题,目前尚无有效的药物治疗方法。加速开发可卡因使用障碍药物的一种策略是,根据已批准用于人类的药物与已知对成瘾至关重要的靶点相互作用的能力,对这些药物进行重新利用。两种这样的药物,洛卡塞林(Belviq;一种具有5-羟色胺[5-HT]2C受体激动剂特性的药物)和丁螺环酮(Buspar;一种具有5-HT1A受体部分激动剂和多巴胺D3/D4受体拮抗剂特性的药物),可以使恒河猴的可卡因自我给药量适度减少。本研究评估了洛卡塞林和丁螺环酮混合物(相对于每种药物的半数抑制剂量[ID50],固定剂量比为3:1、1:1和1:3)在2只雄性和2只雌性恒河猴的渐进比率强化程序下,减少对0.032mg/kg/次可卡因反应的有效性。剂量相加分析用于确定药物混合物的效果是否与洛卡塞林和丁螺环酮之间相加相互作用所预测的效果不同。单独给予洛卡塞林和丁螺环酮时,以及将它们作为洛卡塞林+丁螺环酮的3:1、1:1和1:3固定比例混合物给药时,均观察到可卡因自我给药量的剂量依赖性减少。洛卡塞林+丁螺环酮1:1混合物对可卡因自我给药的效果是超相加的,而3:1和1:3混合物的效果是相加的。总之,这些结果表明,包含洛卡塞林和丁螺环酮混合物的联合疗法在治疗可卡因使用障碍方面可能比单独使用任何一种药物更有效。(PsycINFO数据库记录(c)2018美国心理学会,保留所有权利)